Please login to the form below

OPEN Health mobilised to support outcomes with gene and other advanced therapies

Harnessing the power of collaborations to bring real insights and improve outcomes

The imminent explosion of gene and other advanced therapies brings with it a lot of hope and expectation along with unprecedented challenges faced by bio-pharma - big and small.

The power of the rare disease community has to be harnessed to get these potentially life changing treatments into health systems and to patients in a timely and sustainable fashion.

These are rapidly evolving and exciting times where everyone is learning together and collaboration is key to ensure best practice and novel approaches see widespread adoption.

OPEN Health brought together our existing knowledge in the space to develop experience based thinking on the topics of creating insight and value for gene and other advanced therapies. In addition OPEN Health always values opinion leaders in a particular field and were therefore delighted to be able to interview Nicki Redfern from bluebird bio to hear about their progress and the evolving landscape.

Finally we focus on what we see as a key challenge that requires a new approach. This is how do you deliver effective and sustained outcomes monitoring following initiation of one of these innovative therapies. Read our thinking in this space here.

Pink divider

Get in touch

For more information contact Gavin Jones | Director of Rare Disease | OPEN Health
GavinJones@OpenHealthGroup.com

+44 (0) 7795 038952

30th October 2019

Share

Company Details

OPEN Health

+44 1628 481112

Contact Website

Address:
The Weighbridge
Brewery Courtyard
High Street
Marlow
Buckinghamshire
SL7 2FF
United Kingdom

Latest content on this profile

Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications
OPEN Health
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.
OPEN Health
Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?
A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest. This blog has been written to provide commentary on a topical issue relating to the use of Patient-Reported Outcomes (PROs) in oncology trials.
OPEN Health
Spotlight interview: 15 minutes on insights and market research in pharma
Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma
OPEN Health
OPEN Health reflections on the World Orphan Drug Congress in Barcelona
Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications practices took away from the discussions and presentations.
OPEN Health
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the care pathway for a patient, there appear to be inconsistencies within the same pharmaceutical organisations as to how patient journey mapping is defined.
OPEN Health